
Biofrontera Inc BFRI.OQ BFRI.O is expected to show a rise in quarterly revenue when it reports results on May 15 for the period ending March 31 2025
The Woburn Massachusetts-based company is expected to report a 33.3% increase in revenue to $10.55 million from $7.91 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biofrontera Inc is for a loss of 21 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biofrontera Inc is $10.50, above its last closing price of $0.68.
This summary was machine generated May 13 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)